MUMBAI (Reuters) - Biotechnology firm Biocon Ltd(BION.NS) could file a prospectus for a share listing for its research services business arm Syngene International within the next two months, two ...

The collaboration will combine Syngene’s preclinical development expertise with VivaMed's AI-generated therapeutic hypotheses.

VivaMed BioPharma (VivaMed), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to discover and advance repurposed and improved therapeutic assets, today announced a ...

VivaMed BioPharma and CRDMO Syngene International are partnering on AI-powered discovery to bolster VivaMed’s validation infrastructure.

Continued inventory correction for Syngene’s largest commercial biologics product drags earnings for a second straight quarter.

BENGALURU (Reuters) -India's Syngene International Ltd aims to supply half-a-million vials of COVID-19 drug remdesivir through its local distribution partners next month, its top executive said, as ...

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), reports that that its newly upgraded biologics facility (Unit 3) in Bangalore, India, will be ...

Johnson & Johnson expands its Tar Heel State presence with $2 billion investment, and Syngene sites first U.S. facility in Baltimore. Johnson & Johnson is expanding its footprint in North Carolina ...

Syngene had successfully demonstrated the small-scale synthesis of a novel vascular calcification inhibitor API from lab-scale to tox-batch manufacturing. This was following the request of a pharma ...

Syngene has embarked on evaluating bioequivalence of an injectable for type-2 diabetes and weight management. This was after a global pharma company was scouting for a partner to outsource its human ...

The average one-year price target for Syngene International (NSE:SYNGENE) has been revised to 841.63 / share. This is an increase of 11.27% from the prior estimate of 756.40 dated July 5, 2023. The ...

Syngene International will partner with Zumutor Biologics to screen target antigens against Zumutor’s human antibody libraries, with the goal of discovering and characterizing novel antibody clones.